Ascletis Initiates Phase IIa Trial of Oral GLP-1R Agonist ASC30 for Obesity

Ascletis Pharma announced the first participants have been dosed in a Phase IIa clinical trial (NCT07002905) evaluating ASC30, a novel small molecule ...
Home/KnloSights/Clinical Trial Updates/Ascletis Initiates Phase IIa Trial of Oral GLP-1R Agonist ASC30 for Obesity